

Disclosures

Personal Commercial (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---------------------------|--------------------------|--------------------|
| Self | | | |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Bristol-Myers Squibb Company | Research/Research Grants | Significant (>= \$5,000) | Other |
| Takeda Pharmaceuticals North America, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | General Cardiology |

Additional Personal Commercial Disclosures for Education Activities (2)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------|---------------------------|--------------------|------------------------------------|
| Self | | | |
| MLI Education | Speaker's Bureau | Modest (< \$5,000) | Other |
| Teledoc | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|-----------------------|--------------------|------------------------------------|
| Self | | | |
| MLI Education | Speaker's Bureau | Modest (< \$5,000) | Other |
| Teledoc | Other - Case reviewer | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Clinical Trial Enroller (12)

| Trial Name | Trial Sponsor | Trial Funding Source |
|--|-------------------------------|----------------------|
| AIRES HM3 | Abbott Laboratories | |
| ATRIUM | Bristol Myers Squibb | |
| CK-3773274 for oHCM | Cytokinetics, Inc. | |
| PROACTIVE-HF | Endotronix, Inc. | |
| Surgical Interventions for Moderate Ischemic Mitral Regurgitation | Mount Sinai Medical Center | NIH-NHLBI |
| Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic | Mount Sinai Medical Center | NIH-NHLBI |
| VALOR-HCM | MyoKardia | |
| MAVA-LTE | MyoKardia | |
| Prognostic Value of Coronary Flow Reserve in Patients with Ischemic Heart Disease | National Institutes of Health | |
| REBIRTH | NHLBI | |
| LOFT-HF | Ohio State University | |
| GUIDE-HF | St Jude Medical | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 12/12/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 12/12/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 12/12/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 12/12/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.